Table 3

Net reclassification improvement due to the biomarkers risk score

Predicted risk without biomarkers risk scorePredicted risk with biomarkers risk score
Participants with type 2 diabetes (n=434)<10%10–20%20–35%>35%UpDown
 <10%18 (40.9)22 (50.0)4 (9.1)0 (0)
 10–20%19 (16.2)40 (34.2)40 (34.2)18 (15.4)130 (30.0)57 (13.1)
 20–35%3 (2.3)17 (13.1)64 (49.2)46 (35.4)
 >35%0 (0)5 (3.5)13 (9.1)125 (87.4)
Participants with NFG (n=1897)
 <10%665 (84.8)99 (12.6)20 (2.6)0 (0)
 10–20%264 (42.0)233 (37.0)119 (18.9)13 (2.1)316 (16.7)486 (25.6)
 20–35%36 (11.3)120 (37.5)99 (30.9)65 (20.3)
 >35%2 (1.2)21 (12.8)43 (26.2)98 (59.8)
  • Results are shown as number (%)

  • Net reclassification improvement: 25.7% (SE 0.012), p<0.0001.

  • NFG, normal fasting glucose.